Overt Hepatic Encephalopathy Market is Booming Worldwide. The market size is supposed to increase at a decent compound annual growth rate (CAGR) during the Study Period [2019-2032], Evaluates DelveInsight

The upcoming therapy, Rifaximin (SSD), has the potential to create a significant positive shift in the Overt Hepatic Encephalopathy market size. Topline data of Phase II study for the treatment of OHE showed treatment benefit with no significant safety concerns. Based on the results, the Phase III study is planned. 

LAS VEGAS, April 5, 2022 /PRNewswire/ -- DelveInsight's "Overt Hepatic Encephalopathy Market" report provides a thorough comprehension of the Overt Hepatic Encephalopathy historical and forecasted epidemiology and the Overt Hepatic Encephalopathy market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Overt Hepatic Encephalopathy market report also proffers an analysis of the current Overt Hepatic Encephalopathy treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

Some of the necessary takeaways from the Overt Hepatic Encephalopathy Market Research Report 

• Several key pharmaceutical companies, including Axcella Health, Inc., Vedanta Biosciences, Patricia Bloom, Salix Pharmaceuticals, Bausch Health, and others, are developing novel products to improve the Overt Hepatic Encephalopathy treatment outlook. 
• Overt Hepatic Encephalopathy Market is supposed to grow because of an increasing diagnosed prevalence, emergence in novel targeted therapies, and less competition in the market. Nevertheless, the Overt Hepatic Encephalopathy Market may be hindered by adverse events associated with the therapies, not very robust pipeline, and disease burden with challenges in the Overt Hepatic Encephalopathy diagnosis. 
• With increasing cases and awareness, more companies are focusing on the therapeutic pipeline-related HE and its subtypes. As a result, in the upcoming years, several new products such as Rifaximin (Bausch Health), AXA1665 (Axcella Health), and VE303 (Vedanta Biosciences) are expected to enter the market. 

For further information on Market Impact by Therapies, visit: Overt Hepatic Encephalopathy Drugs Market Analysis 

Hepatic encephalopathy is a brain disorder that develops in some individuals with liver disease. In Overt Hepatic Encephalopathy or Severe Hepatic encephalopathy, a person experiences impaired mental and neuro motor functioning with apparent signs of mental confusion, gross disorientation, drowsiness, and coma.

DelveInsight estimates that among 7MM, the United States had the highest diagnosed Hepatic Encephalopathy prevalent cases with 206,632 cases in 2021.

The Overt Hepatic Encephalopathy Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total Diagnosed Hepatic Encephalopathy Prevalent Cases 
• Diagnosed Prevalent Cases of Overt Hepatic Encephalopathy
• Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy
• Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy 

Get a complete epidemiological segmentation breakdown @ Overt Hepatic Encephalopathy Epidemiological Analysis

Overt Hepatic Encephalopathy Treatment Market 

The treatment of acute or persistent Hepatic Encephalopathy has changed very little during the past years. However, with newer agents under investigation, the available treatment options are supposed to increase in upcoming years. Until then, treatment options are limited to correcting or removing precipitating causes, dietary changes, and pharmacologic approaches focused on using non-absorbable disaccharides.

The two primary forms of medical therapy for Hepatic Encephalopathy are non-absorbable disaccharides (lactitol and lactulose) and non-absorbable antibiotics (Rifaximin). The hyperammonemia and inflammation due to urea breakdown in cirrhotic have led to the development of Hepatic Encephalopathy treatments that target gut bacteria. 

Unfortunately, not all patients can tolerate these agents. For patients who cannot tolerate the sweet taste of lactulose, a powder packet is available. For patients who develop gastrointestinal bloating or debilitating diarrhea, a second-line agent is considered. Xifaxan (Rifaximin) tablets (550 mg) developed and marketed by Salix Pharmaceuticals (a subsidiary of Valeant Pharmaceuticals) is approved for the reduction in risk of Overt Hepatic Encephalopathy recurrence in patients ≥ 18 years of age. Similar molecule Rifaximin (SSD) from Salix Pharmaceuticals is under clinical evaluation for the Overt Hepatic Encephalopathy treatment.

The second-line agents include oral antibiotics (neomycin, metronidazole, and rifaximin) that can reduce urease-producing bacteria in the intestines, resulting in decreased ammonia production and absorption through the gastrointestinal tract. Both neomycin and metronidazole have been used for many years to treat Hepatic Encephalopathy and are inexpensive. However, the potential side effects of neomycin (ototoxicity and renal insufficiency) and metronidazole (peripheral neuropathy) limit their use. 

The third line agents available for patients who cannot tolerate the above agents or still have persistent or episodic Hepatic Encephalopathy on the above agents are sodium benzoate, zinc, or bromocriptine. In addition, patients with unique situations may also benefit from an agent in this class. Sodium benzoate is inexpensive but is associated with a significant sodium load and gastrointestinal side effects. 

There are many key players such as Salix Pharmaceuticals/Bausch Health, Axcella Health, Inc. and several others that are developing Overt Hepatic Encephalopathy potential drugs, which are in mid and late-stage developments to be approved shortly. 

Overt Hepatic Encephalopathy Market Dynamics 

Overt Hepatic Encephalopathy Market to observe growth due to the increasing prevalent population of the disease, which will lead to a surge in treatment options. The shortfall of approved therapies might provide suitable space for emerging therapies, the clinical trial activity is not very robust, yet few novel therapies are being evaluated. Thus, the Overt Hepatic Encephalopathy market opportunity for them could be excellent. Also, medications with better safety and effectiveness, which provide an optimum cure, are the current unmet need of the Overt Hepatic Encephalopathy market; low cost and less time-consuming therapy are required in the market.

The growth of the Overt Hepatic Encephalopathy Market may be hindered by the lack of understanding of the clinical course, and clinical relevance may represent a missed opportunity to make the correct diagnosis. Also, most of the available pharmacological therapies have limited use as they only provide temporary relief. And the Overt Hepatic Encephalopathy pipeline is not very robust; more efficacious and targeted therapies are required. In addition to this, the growth of the market may hinder due to strict pricing and reimbursement policies, possible arrival of generics, and the lengthy diagnostic procedures which often lead to delayed diagnosis and unsatisfactory patient care. 

Scope of the Overt Hepatic Encephalopathy Market Insight Report 

• Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
• Study Period: 3-year historical and 11-year forecasted analysis (2019-2032).
• Overt Hepatic Encephalopathy Markets Segmentation: By Geographies and By Overt Hepatic Encephalopathy Therapies (Historical and Forecasted, Current and Upcoming) 
• Dominant Market Companies investigating its candidates for Overt Hepatic Encephalopathy: Axcella Health, Inc., Vedanta Biosciences, Patricia Bloom, Salix Pharmaceuticals, Bausch Health, and several others. 
• Analysis: Comparative and conjoint analysis of emerging therapies. 
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Overt Hepatic Encephalopathy Therapeutics Market

Table of Contents 

Browse full report with detailed TOC with charts, figures, tables @ Overt Hepatic Encephalopathy Diagnostics Market Report

View Other Reports

Hepatic Colorectal Metastasis Pipeline 

"Hepatic - Colorectal Metastasis Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development pipeline scenario and growth prospects across the Hepatic - Colorectal Metastasis market with key companies involved like Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc, Umecrine Cognition, Mallinckrodt Therapeutics, Vedanta Biosciences, Patricia Bloom, and others.

Overt Hepatic Encephalopathy - Epidemiology 

DelveInsight's Overt Hepatic Encephalopathy Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Overt Hepatic Encephalopathy.

Overt Hepatic Encephalopathy Pipeline

"Overt Hepatic Encephalopathy Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Overt Hepatic Encephalopathy market. A detailed picture of the Overt Hepatic Encephalopathy pipeline landscape is provided, which includes the disease overview and Overt Hepatic Encephalopathy treatment guidelines. 

Hepatic Encephalopathy Market

DelveInsight's Hepatic Encephalopathy - Market Insights, Epidemiology and Market Forecast - 2032 report provides a detailed overview of the disease and in-depth understanding of the disease,  historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends, market drivers and barriers as well as key  Hepatic Encephalopathy companies involved such as Salix Pharmaceuticals, Bausch Health, Axcella Health, Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix, and others.

Novel Drug Delivery Devices Market

DelveInsight's 'Novel Drug Delivery Devices - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Novel Drug Delivery Devices and the historical and forecasted Novel Drug Delivery Devices market trends, globally, which comprises North America, Europe, APAC, and RoW.

Multiple Organ Dysfunction Syndrome Market

DelveInsight's "Multiple Organ Dysfunction Syndrome Market Insights, Epidemiology, and Market Forecast-2030" report proffers thorough details into the Memory Disorder market, epidemiology, pipeline therapies, and key companies including Dart Neuroscience, Corcept Therapeutics, Cerecin, and various others. 

Narcolepsy Market

DelveInsight's 'Narcolepsy–Market Insights, Epidemiology, and Market Forecast-2030' report provides deep insights into the Narcolepsy market, epidemiology, pipeline therapies, and key companies including Cephalon Inc., Jazz Pharmaceuticals, and several others.

Browse Blog Posts

• Hepatic Encephalopathy - Lack of active pipeline products
• Hepatic Encephalopathy - An ailment of the liver to the brain
• Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

 About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg